Aduro BioTech is a technology company.
Aduro BioTech has raised $56.0M across 1 funding round.
Aduro BioTech has raised $56.0M in total across 1 funding round.
Aduro Biotech was a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing immunotherapies that harness the body's immune system to treat challenging diseases like cancer, autoimmune disorders, and inflammatory conditions.[1][3] It targeted pathways such as STING (Stimulator of Interferon Genes) and APRIL (A Proliferation Inducing Ligand), with key candidates including ADU-S100 (MIW815) for solid tumors and lymphomas, and BION-1301 for IgA nephropathy; the company collaborated with major pharmaceutical firms to advance its pipeline.[1][4] Originally serving patients with unmet medical needs through innovative platforms like Live Attenuated Double-Deleted Listeria (LADD), STING activators, and B-select antibodies, Aduro built early momentum via an IPO in 2015, raising over $173 million total, before merging with Chinook Therapeutics in 2019 and being acquired by Novartis for $3.5 billion in 2023.[2][5][6]
Founded in 2000 in Berkeley, California, Aduro Biotech—formerly Oncologic, Inc. until 2008—emerged from research into immunotherapy platforms with transformative potential in cancer care.[2][3][6] Key founders included figures like Dirk Brockstedt and Sushil Prabhu, though specifics on early team backgrounds are limited in available records; the idea stemmed from proprietary technologies like LADD Listeria vectors for immune stimulation.[3] Early traction came through advancing candidates into clinical trials, culminating in a 2015 IPO that fueled pipeline expansion amid growing interest in immuno-oncology; pivotal moments included partnerships with global pharma and the 2019 merger with Chinook Therapeutics, enhancing kidney disease expertise, leading to the 2023 Novartis acquisition.[1][2][5]
Aduro rode the 2010s immuno-oncology wave, capitalizing on breakthroughs in checkpoint inhibitors and innate immune activation amid a surge in cancer immunotherapy investments post-2015 IPO boom.[1][2] Timing aligned with market forces like rising autoimmune disease prevalence and STING pathway validation, positioning Aduro to influence biotech ecosystems through platform licensing and talent development in Berkeley's innovation hub.[3][5] Its merger with Chinook and Novartis buyout amplified impact, integrating kidney-focused assets into big pharma pipelines and validating smaller biotechs' role in precision medicine ecosystems.[5]
Post-2023 Novartis acquisition, Aduro's technologies live on within a major pharma powerhouse, likely accelerating STING and APRIL candidates toward later-stage trials or approvals in oncology and nephrology.[1][4][5] Trends like next-gen immunotherapies and combo regimens with ADCs or bispecifics will shape their evolution, potentially expanding influence via Novartis' global reach. This trajectory underscores Aduro's legacy: from Berkeley startup to $3.5B exit, exemplifying biotech's high-stakes innovation in harnessing immunity against unmet needs.[5]
Aduro BioTech has raised $56.0M in total across 1 funding round.
Aduro BioTech's investors include Canaan Partners, Johnson & Johnson Innovation.
Aduro BioTech has raised $56.0M across 1 funding round. Most recently, it raised $56.0M Series C in June 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2014 | $56.0M Series C | Canaan Partners, Johnson & Johnson Innovation |